Full-Time
Senior Manager
Landmark Bio
51-200 employees
Cell and gene therapy CDMO services
No salary listed
Belmont, MA, USA
In Person
 Engineering Management (1) |
|---|
- Bachelor’s degree in Information Technology, Computer Science, or related field
- 8+ years of IT experience, preferably in biotech, pharma, or regulated industry
- Strong hands-on experience with end-user systems, infrastructure, and networking
- Experience supporting cloud, SaaS, and on-premise environments
- Experience working in GxP / regulated / manufacturing / lab environments preferred
- Experience managing vendors and managed service providers
- Strong troubleshooting and problem-solving skills
- Ability to work independently in a small, fast-paced organization
- Maintain and support on-premise and cloud-hosted infrastructure, end-user devices, networking, and business applications
- Ensure high availability, performance, and security of IT systems
- Support regulated GxP laboratory and manufacturing environments
- Manage user accounts, access control, device provisioning, and software deployment
- Oversee backup, disaster recovery, and monitoring systems
- Platforms include: Microsoft 365, SharePoint, Teams, Office; Windows Server / Windows 10/11; Meraki network / Palo Alto firewall / VPN; FreshService, CyberReason, Kaseya, IT Glue, Autotask, Rocket Cyber, BullPhish, RMM, Spanning, Unitrends; Building security and monitoring systems; End-user hardware, printers, and conference room AV; Business systems including Smartsheet, Veeva, SAP, DocuSign, Okta, Adobe; Lab instrument user accounts and software installs
- Ensure timely and effective IT support for employees and laboratory users
- Improve reliability, usability, and performance of end-user systems
- Partner with business teams to evaluate and implement new applications
- Support onboarding, offboarding, and equipment lifecycle management
- Coordinate with external IT vendors and service providers
- Monitor performance, costs, and service quality
- Assist with contract renewals, budgeting, and vendor selection
- Maintain IT policies, procedures, and documentation
- Support CSA / SDLC / GxP / audit readiness activities
- Ensure systems meet cybersecurity and data protection standards
- Support validation and regulated system controls where required
- Lead small to mid-size IT projects and system implementations
- Identify opportunities to improve efficiency, automation, and reliability
- Support site expansion, lab build-out, and new system deployments
Landmark Bio is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. It provides end-to-end services including drug development consulting, process analytical development, cGMP manufacturing, and CMC regulatory consulting to turn research into clinical programs. Its offerings are tailored services rather than products, delivered through collaborations with academia, physicians, biopharma, and research hospitals to address manufacturing costs and complexities. Its goal is to help programs reach clinical trials and commercial use faster while meeting regulatory standards and budget constraints, increasing patient access to advanced therapies.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Watertown, Massachusetts
Founded
N/A
Simplify's Take
What believers are saying
- Artis BioSolutions acquisition on April 2, 2025, expands end-to-end preclinical to commercial solutions.
- ARPA-H award integrates advanced upstream, downstream technologies to overcome batch limitations.
- Deep expertise from 150 tech transfers, 46 BLAs, and 45 approved products attracts biopharma clients.
What critics are saying
- Larger CDMOs like Catalent and Lonza erode market share in 12-24 months.
- Galapagos terminates CAR-T contract after batch failures in 6-12 months.
- Artis diverts resources from Landmark within 3-6 months post-acquisition.
What makes Landmark Bio unique
- Landmark Bio offers modular cGMP suites for LVV, AAV, cell processing, mRNA, and novel modalities.
- Secured up to $18.3M ARPA-H funding on April 1, 2026, for continuous EV manufacturing platform.
- Signed manufacturing agreement with Galapagos for oncology CAR-T cell therapy.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Landmark Bio who can refer or advise you
Benefits
Health Insurance
Unlimited Paid Time Off
Flexible Work Hours
Hybrid Work Options
Professional Development Budget
Conference Attendance Budget
Wellness Program
Mental Health Support
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Phone/Internet Stipend
Home Office Stipend
Company News
Artis BioSolutions has appointed Dr Kate Broderick as Chief Scientific Innovation Officer, effective 9 February 2026. She will lead scientific strategy and innovation initiatives across the company's platform for developing and manufacturing genetic medicines. Dr Broderick brings over 25 years of experience in nucleic acid medicine and DNA- and RNA-based vaccine development. Most recently, she served as Chief Innovation Officer at Maravai LifeSciences. Previously, at Inovio Pharmaceuticals, she led R&D teams that advanced multiple clinical-stage programmes, including a DNA-based COVID-19 vaccine through Phase 3 testing, and secured over $100 million in non-dilutive funding. The appointment comes as Artis prepares to close its acquisition of Syngoi Technologies, expected in the first quarter of 2026. Dr Broderick holds a PhD in Molecular Genetics from the University of Glasgow.
Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, today announced its launch, alongside its...